Literature DB >> 17465491

Recent advances in basic and clinical aspects of inflammatory bowel disease: which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease?

Hitoshi Asakura1, Kenji Suzuki, Terasu Honma.   

Abstract

There are four steps in the interaction between intestinal microbes and mucosal inflammation in genetically predisposed individuals from the viewpoints of basic and clinical aspects of inflammatory bowel disease (IBD). The first step is an interaction between intestinal microbes or their components and intestinal epithelial cells via receptors, the second step an interaction between macrophages and dendritic cells and mucosal lymphocytes, the third step an interaction between lymphocytes and vascular endothelial cells, and the fourth step an interaction between lymphocytes and granulocytes producing proinflammatory cytokines or free radicals and mucosal damage and repair. Recent therapeutic approaches for IBD aim to block these four steps in the intestinal inflammation of patients with IBD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465491      PMCID: PMC4146834          DOI: 10.3748/wjg.v13.i15.2145

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  50 in total

Review 1.  Th17: an effector CD4 T cell lineage with regulatory T cell ties.

Authors:  Casey T Weaver; Laurie E Harrington; Paul R Mangan; Maya Gavrieli; Kenneth M Murphy
Journal:  Immunity       Date:  2006-06       Impact factor: 31.745

Review 2.  Probiotics and prebiotics in chronic inflammatory bowel diseases.

Authors:  Julia B Ewaschuk; Levinus A Dieleman
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

3.  Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria.

Authors:  Nobuhiko Kamada; Tadakazu Hisamatsu; Susumu Okamoto; Toshiro Sato; Katsuyoshi Matsuoka; Kumiko Arai; Takaaki Nakai; Akira Hasegawa; Nagamu Inoue; Noriaki Watanabe; Kiyoko S Akagawa; Toshifumi Hibi
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

4.  Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997.

Authors:  S K Yang; W S Hong; Y I Min; H Y Kim; J Y Yoo; P L Rhee; J C Rhee; D K Chang; I S Song; S A Jung; E B Park; H M Yoo; D K Lee; Y K Kim
Journal:  J Gastroenterol Hepatol       Date:  2000-09       Impact factor: 4.029

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes.

Authors:  K Suzuki; K Sugimura; K Hasegawa; K Yoshida; A Suzuki; K Ishizuka; K Ohtsuka; T Honma; R Narisawa; H Asakura
Journal:  Scand J Gastroenterol       Date:  2001-12       Impact factor: 2.423

7.  Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column.

Authors:  Koji Sawada; Tetsuichiro Muto; Takashi Shimoyama; Masamichi Satomi; Toshio Sawada; Hirokazu Nagawa; Nobuo Hiwatashi; Hitoshi Asakura; Toshifumi Hibi
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

8.  Natalizumab for active Crohn's disease.

Authors:  Subrata Ghosh; Eran Goldin; Fiona H Gordon; Helmut A Malchow; Jørgen Rask-Madsen; Paul Rutgeerts; Petr Vyhnálek; Zdena Zádorová; Tanya Palmer; Stephen Donoghue
Journal:  N Engl J Med       Date:  2003-01-02       Impact factor: 91.245

9.  Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract.

Authors:  Ryuichi Okamoto; Tomoharu Yajima; Motomi Yamazaki; Takanori Kanai; Makio Mukai; Shinichiro Okamoto; Yasuo Ikeda; Toshifumi Hibi; Johji Inazawa; Mamoru Watanabe
Journal:  Nat Med       Date:  2002-08-26       Impact factor: 53.440

10.  Regulation of murine intestinal inflammation by reactive metabolites of oxygen and nitrogen: divergent roles of superoxide and nitric oxide.

Authors:  C F Krieglstein; W H Cerwinka; F S Laroux; J W Salter; J M Russell; G Schuermann; M B Grisham; C R Ross; D N Granger
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

View more
  4 in total

Review 1.  Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Authors:  Dimitrios Damaskos; George Kolios
Journal:  Br J Clin Pharmacol       Date:  2008-02-12       Impact factor: 4.335

Review 2.  Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad.

Authors:  Maciej Chichlowski; Laura P Hale
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-10-16       Impact factor: 4.052

Review 3.  Nutraceuticals' Novel Formulations: The Good, the Bad, the Unknown and Patents Involved.

Authors:  Nada A Helal; Heba A Eassa; Ahmed M Amer; Mohamed A Eltokhy; Ivan Edafiogho; Mohamed I Nounou
Journal:  Recent Pat Drug Deliv Formul       Date:  2019

4.  WISP1 Is Increased in Intestinal Mucosa and Contributes to Inflammatory Cascades in Inflammatory Bowel Disease.

Authors:  Qi Zhang; Cuiping Zhang; Xiaoyu Li; Yanan Yu; Kun Liang; Xinzhi Shan; Kun Zhao; Qinghui Niu; Zibin Tian
Journal:  Dis Markers       Date:  2016-06-15       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.